Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA
Authors:
- 1 January 2019
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 106, 133-143
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (CA207468)
- Thomas Jefferson University (5P30CA056036-17)
- Pennsylvania Department of Health (SAP# 4100062221)
- Jamie Lieberman Memorial Endowment Trust
This publication has 52 references indexed in Scilit:
- Circulating cell free DNA: Preanalytical considerationsClinica Chimica Acta, 2013
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerNew England Journal of Medicine, 2013
- Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and ErlotinibClinical Cancer Research, 2012
- Quantitative analysis of cell-free DNA in the plasma of gastric cancer patientsOncology Letters, 2012
- Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor CellsJNCI: Journal of the National Cancer Institute, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Effect of Adjuvant Chemotherapy on Integrity of Free Serum DNA in Patients with Breast CancerAnnals of the New York Academy of Sciences, 2008
- Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast CancerClinical Cancer Research, 2006
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Quantification of Free Circulating DNA As a Diagnostic Marker in Lung CancerJournal of Clinical Oncology, 2003